Roche Holding AG (ROGZ.XC)
| Previous close | 245.75 |
| Open | 246.90 |
| Bid | 247.50 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 245.90 - 248.50 |
| 52-week range | 213.00 - 279.85 |
| Volume | |
| Avg. volume | 188,185 |
| Market cap | 200.171B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 17.30 |
| EPS (TTM) | 14.31 |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | 9.60 (3.88%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
GlobeNewswireRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy1 This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCLData were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking oral presentatio
Business WireGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif., June 15, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of
ZacksRoche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.
